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http://www.wjso.com/content/12/1/378RESEARCH Open AccessImplanting totally implantable venous access
port via the internal jugular vein guided by
ultrasonography is feasible and safe in patients
with breast cancer
Jie Zhou1,2†, Shikun Qian3†, Weixing He2, Guodong Han2, Hongsheng Li2* and Rongcheng Luo1*Abstract
Background: Because of long-term use for chemotherapy and fluid administration in cancer patients, a totally
implantable venous access port (TIVAP) has been advised as a feasible catheter. The purpose of this study was to
evaluate the effectiveness and safety of ultrasound (US)-guided internal jugular vein (IJV) puncture for TIVAP
implantation in patients with breast cancer.
Methods: We reviewed the medical records of 492 patients who underwent US-guided IJV puncture for TIVAP
implantation at our oncology department between 2010 and 2013. Indications, surgical complications, and early
and long-term complications were analyzed.
Results: All TIVAPs were implanted successfully. Indications for TIVAP were chemotherapy alone (88 patients),
chemoradiotherapy (387 patients), surgery (12 patients), and parenteral nutrition (5 patients). Complications were
observed in 65 (13.21%) patients. The median duration of the TIVAP was 359 days (range, 28 to 712 days) without
damage to the port or catheter, or leakage of drugs outside of the port system.
Conclusions: A TIVAP can be employed for chemotherapy and parenteral nutrition on the implantation day. Using
a US-guided IJV puncture to completely implant a TIVAP is feasible and safe in patients with breast cancer.
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A totally implantable venous access port (TIVAP) pro-
vides a simple and safe means of accessing the vascular
system for intravenous delivery of chemotherapeutic drugs
and supportive care, which are widely used in clinical
oncology [1,2]. In the treatment of breast cancer, chemo-
therapy regimens with a duration of up to 6 months are
commonly required [3]. Secure venous access is desirable
for these treatments as chemotherapy drugs are toxic
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unless otherwise stated.docetaxel-containing regimens are frequently used as
first-line treatments for breast cancer patients. There-
fore, the placement of a TIVAP at the beginning of a
chemotherapy regimen with potentially necrosis-inducing
agents is required [5]. A TIVAP can be implanted via the
basilic vein, subclavian vein, external jugular vein, or the
internal jugular vein (IJV). Since patients with breast can-
cer must undergo ipsilateral radiotherapy and blood pres-
sure measurements or since they may carry heavy objects
using the contralateral arm, the IJV and subclavian vein
of the contralateral side are the suitable choices for
TIVAP placement. However, puncturing of the subcla-
vian vein is associated with considerable complications,
including pneumothorax, hemothorax, injury of large
vessels, and catheter pinch-off within the costoclavicu-
lar space [1,6]. Thus, the IJV is considered as the pri-
mary effective vein.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.wjso.com/content/12/1/378From January 2010, the TIVAP via IJV approach has
been used in our institution and the TIVAP is used
immediately on the implantation day. A port TIVAP
is implanted into the healthy side, and the catheter is
introduced via the IJV to the superior vena cava (SVC).
Herein, we report on our observations associated with




This was a retrospective study including 492 patients
with breast cancer. Patient demographics and characte-
ristics are shown in Table 1. Of the 492 patients, 5 were
male and 487 were female; they had a median age of
48.66 years (range, 22–73 years). All patients under-
went fluid administration and/or chemotherapy. Between
January 2010 and December 2013, all patients underwent
TIVAP placement via the IJV or subclavian vein to the
SVC. All patients were followed-up until TIVAP removal,
death, or hospital discharge. The procedure and its pos-
sible complications were explained to patients, and writ-
ten informed consent was obtained.Table 1 Demographics of the study population (n = 492)
Characteristics Value Percentage
Median age (years) 48.66 ± 11.05




Median BMI 24.72 ± 2.72




Right internal jugular vein 251 51.02
Left internal jugular vein 229 46.54
Right subclavian vein 5 1.02
Left subclavian vein 7 1.42
Treatment
Chemoradiotherapy 387 78.66
Chemotherapy alone 88 17.89
Surgery 12 2.44
Nutritional therapy 5 1.02
Follow-up period, days
Median days of the catheter 359.13 ± 183.88
Range 28–712
Total catheter days 176,694Main equipment
The port system had two components: a silicone inter-
mediate-sized reservoir with a large central injection
septum made of silicone rubber and a polyurethane cathe-
ter with a Groshong® valve (Bard Port isp Access System,
Salt Lake City, USA).Implantation procedures
Prior to surgical implantation, blood count, prothrombin
time, and routine biochemistry parameters were obtained.
Patients were placed in a supine position on the operative
table. Catheter length was measured according to body
surface prior to the procedure. Local anesthesia was ad-
ministrated subcutaneously, restricted to the area of the
port implantation and the venous puncture. No routine
prophylactic antibiotics were administered. A standard
surgical sterile technique was employed in all cases, in-
cluding a surgical scrub.
The IJV was the preferred access site. The subclavian
vein was the second choice for the surgical procedure.
After local anesthetization with 1% lidocaine, the IJV was
punctured under direct ultrasound visualization (10 MHz
ultrasound transducer, Sonosite S series, Bothell, WA,
USA) using an 18-gauge needle. A subcutaneous pocket
was created on the contralateral side of the anterior chest
wall while avoiding any possible radiation fields. A 2-cm
skin incision was made with an 11-blade scalpel and anes-
thetized with 1% lidocaine. The subcutaneous tissues of
the port pocket and tunnel were anesthetized with 1%
procaine with epinephrine (1:200,000). Through a blunt
and sharp dissection, the port pocket was created. Using a
tunneling device, the catheter was tunneled from the
pocket incision to the IJV puncture site. A port was con-
nected to the indwelling catheter through a subcutaneous
tunnel and was implanted in the pocket. The wound was
closed with a 4-0 resorbable suture. X-ray surveillance was
subsequently used for the silicone rubber and polyureth-
ane catheter placement. The catheter tip was positioned at
the junction of the right atrium to the SVC.
For patients who required continuous infusion, the nee-
dle and infusion line set were changed every week. A total
of 10 mL of heparinized saline solution (100 IU/mL) was
administered as a flush solution before needle removal
(Figures 1, 2 and 3).Patient follow-up
TIVAP implantation was performed in breast cancer pa-
tients who required a large number of chemotherapy
regimens and cycles and/or fluid administration. The
early and late complications were all observed and recor-
ded from the day of implantation procedure to December
2013. Variables were recorded as medians and the range
was given. In the 492 patients, the median duration of
Figure 1 TIVAP implantation procedure. US-guided IJV (V) surgical
procedure (A, B). Lines were drawn to create the anatomical landmark,
surgical incision, and puncture site (C). Insertion of a continuous
infusion needle (D).
Figure 3 Catheter tip and port location. X-ray examination for
catheter tip location (A). CT showing location of port and
catheter (B).
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any break to the port system or any leakage of drugs.
Statistical analysis
Statistical analysis was conducted using the SPSS 19.0




TIVAP implantation was performed for chemotherapy
alone (88 patients), chemoradiotherapy (387 patients),
surgery (12 patients), or parenteral nutrition (5 patients).
In total, 176,694 catheter days (average 359 days per pa-
tient; range, 28–712 days) were analyzed. Of these 492Figure 2 The TIVAP was implanted into the contralateral side
to avoid the radiotherapy area.patients, 17 patients did not receive their planned in-
travenous chemotherapy and the TIVAPs were only ef-
fectively used for surgery or parenteral nutrition. In the
remaining patients, the median number of chemothe-
rapeutic cycles after TIVAP implantation was 5 (range,
2–8). Right breast cancer was observed in 236 patients
and left breast cancer in 256 patients. The median time
for the implantation was 32 min (range, 23–50 min).
Complications
The early complications are summarized in Table 2.
Hematoma was observed in 12 patients (in 7 patients
this occurred in the implantation site and in 5 patients
in the implanted pocket) and resolved within 2 weeks
(Figure 4A). Early infection was observed in 2 patientsTable 2 Early complications
Early complications n = 492 Percentage
Hematoma 12 2.44
Cardiac arrhythmia 10 2.03
Arterial puncture 6 1.22
Guide wire bending 3 0.61
Bleeding 2 0.41
Introductory sheath kinking 2 0.41
Pock early infection 2 0.41
Total 37 7.52
Figure 4 Complications of hematoma (A) and infection (B).
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probably due to the catheter tip touching the right atrium.
After replacing the catheter tip on the SVC or changing
body position, the arrhythmia disappeared.
The late complications are summarized in Table 3.
Catheter-associated thrombosis was observed in 12 pa-
tients (2.44%) approximately 12 weeks after implantation.
These patients received warfarin and heparin treatment
and their TIVAP continued to be used without further
complications. Pulmonary thromboembolism was not
observed in any patients. Catheter migration and embo-
lization was documented in 6 patients. Port pocket infec-
tion due to cutting of the skin with the needle during
repeated puncture was observed in 3 patients (0.61%)Table 3 Late complications
Late complications n = 492 Percentage
Catheter-associated venous thrombosis 12 2.44
Catheter migration and embolization 6 1.22
Catheter-related infection 4 0.81
Port pocket infection 3 0.61
Pinch-off syndrome 3 0.61
Total 28 5.69after 3 months of use for chemotherapy and fluid ad-
ministration. Among the 12 patients who were converted
to the subclavian vein, 3 were diagnosed with pinch-off
syndrome.
Patient follow-up
Reasons for TIVAP removal are shown in Table 4. The
TIVAPs of 322 patients were removed at the end of
therapy. Catheter occlusion led to the removal of TIVAP
from 17 patients, 4 removals were due to incurable infec-
tion with bacteremia due to penicillin-resistant staphylo-
coccus aureus, and 1 patient (0.20%) died within 1 month
of implantation because of disease progression.
Discussion
The totally implantable port system was introduced to
the clinic by Dr. Niederhuber in 1982. The main purpose
of a TIVAP in clinical practice is to provide a secure and
comfortable route for cytotoxic drugs for patients with
malignancies and intravenous parenteral nutrition solu-
tions [1,7]. In this study, we evaluated the consequences
of using a TIVAP in patients with breast malignancy,
since there were only a few reports on the use of a TIVAP
in the Chinese population or regarding the US-guided
implantation approach through the IJV [5].
The IJV is located at the apex of the triangle formed
by the heads of the sternocleidomastoid muscle and the
clavicle. The subclavian vein crosses under the clavicle
just medial to the midclavicular point [8]. These veins
are invisible on the skin surface, and were therefore ori-
ginally blindly punctured based on the operator’s ex-
perience. Image guidance can improve the accuracy of
vascular puncture and virtually eliminates the risk of se-
veral complications reported with unguided placement
such as pneumothorax, hemothorax, and nerve injury [9].
None of these complications occurred in patients who
underwent US-guided placement. Under US visualization,
the introducer needle is guided through the skin and
into the vein. The IJV is difficult in obese patients and
therefore conversion to the subclavian venous vein for
TIVAP implantation is indispensable. In our department,
all TIVAPs were implanted via the IJV or subclavian vein
successfully. After implantation, chemotherapy and/or
fluid administration were performed on the same day.
Cardiac arrhythmia and hematoma are the most com-
mon mechanical complications during the insertion ofTable 4 Reasons for removal of TIVAP (n = 492)
Reason n Percentage
End of therapy 322 65.45
Catheter occlusion 17 3.46
Infection 4 0.81
Death 1 0.20
Figure 5 Kaplan-Meier survival curve showing complication-
free catheter duration over time for both study groups. RBC,
complication of right breast cancer; LBC, complication of left
breast cancer.
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observed in 22 (4.47%) patients, which is lower than
in previous studies [5,10]. Cardiac arrhythmia is avoida-
ble with careful catheter placement. Hematoma may be
caused by incorrect artery puncture or abnormal men-
strual periods in breast cancer patients. Local sufficient
compression for 10 to 15 minutes immediately stops
bleeding. With respect to guide wire bending and in-
troductory sheath kinking, we experienced two patients
requiring intraoperative conversion from the IJV to the
subclavian vein. Since one patient died early after the im-
plantation of the TIVAP, for causes unrelated to TIVAP
implantation, good performance status and sufficient
organ function to receive antitumor treatment were veri-
fied before the implantation procedure in order to con-
sider the benefit for patients from TIVAP. The early
infection within the pocket was observed in 2 patients,
probably due to bacteremia from the incision or needle
site, which is consistent with prior reports [10,11]. Appli-
cation of antibiotic ointments and oral antibiotic drugs
were advised.
Thromboembolic complications are the major late po-
tential problem in the long-term management of TIVAPs.
Catheter implantation itself carries a risk of venous
thrombosis [1,12]. In our clinical observation, catheter-
associated venous thrombosis was recorded in 12 (2.44%)
patients. The incidence in previous reports ranges from
0.3% to 23% [5,7,11,13-18]. Vescia et al. reported that low
molecular weight heparin may be ineffective and that a
higher dose may result in a positive outcome [1]. Karthaus
reported that in 439 cancer patients with a central venous
catheter, dalteparin prophylaxis did not reduce the fre-
quency of thromboembolic complications [19]. Sutherland
found that the prompt use of anticoagulation therapy
after the occurrence of venous thrombosis is essential
[12]. Ahn observed that a diluted heparin solution flushed
every month is essential [13]; the incidence of throm-
bosis in their study was lower than in ours, probably as
a result from the different catheter material and struc-
ture [13]. When catheter-related thrombosis was ob-
served, anticoagulant therapy was administrated first in
the current study; if thrombolytic therapy was efficient,
immediate removal of the port was not necessary. Ca-
theter tip thrombosis with the port system is flushable
but there is no aspiration of blood via the tip. In our
department, 10,000 IU heparin over 24 hours is flushed
into the port system for 3 days via a perfusion system,
after which treatment the port system often becomes
effective again.
Catheter migration and embolization were recorded in
6 (1.22%) patients, which is lower than that reported in
previous studies [20], probably due to avoiding excessive
movement and the use of a Groshong® valve catheter in
our department.Catheter-related infection is also a potential long-term
complication in the management of a TIVAP [5], and its
diagnosis if often difficult in the absence of local signs of
inflammation [21]. In our study, the complication was
observed in 4 (0.81%) patients, which was less than the
rate reported in the literature [7,10,11,22-25]. Paired blood
cultures (aerobic and anaerobic) from a peripheral vein
and the central catheter were conducted to evaluate the
possibility of bacteremia. A positive culture of blood from
a central venous catheter indicates contamination of ca-
theter colonization or a catheter-related bloodstream in-
fection. Patients with a negative result require a second
culture for confirmation. Port systems must be removed
in case of persistent bacteremia infection after antibiotic
treatment.
In our study, 3 (0.61%) patients with pinch-off syn-
drome were observed. Their catheters were placed be-
tween the clavicle and the first rib via subclavian vein
access. Nikolaos et al. reported a complication rate of
2.5% [10], which was higher than that in our study. The
variation could be caused by the difference in implan-
tation site.
The distance between the left IJV or the left subcla-
vian vein to the junction of the right atrium and SVC is
greater than on the right side. The catheter length
inserted into the body from the left side is longer than
that from the right, which may cause more complica-
tions. However, in our study, the difference between the
complications of right and left sides was not significant
(Figure 5).
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reported that chemotherapy administration immediately
after a venous port catheter implantation appears safe
without increased acute and chronic complications in an
inpatient setting [17]. However, Narducci et al. found
that a minimal interval of 8 days between placement of
the TIVAP and its first use can reduce complications
[20]. In our study, the overall complication rate of 13.21%
was similar to the 10 to 20% complication rate reported
for several large surgical series in which both chest and
arm ports were placed [9,26]. Our results support clinical
administration of TIVAP on the implantation day.
In our institution, we discuss with our patients the op-
tion of maintaining the port system implanted for up to
2 years after adjuvant breast cancer therapy owing to the
increased risk of relapse within this period. The port sys-
tems may be needed again for palliative chemotherapy
in metastatic patients [1]. Based on our experiences, the
median time of catheter follow-up was 12 months by
heparin flushing of the port system at 1-month intervals,
similar to previous studies [27,28]. No complications re-
garding a breakdown of the port system or drug leakage
were noted during the observation period of 1 to 24
months in our study. Therefore, it is clear that careful
and strict antiseptic handling can avoid contamination
and minimize catheter-related infections.
Conclusions
Antitumor therapy including chemoradiotherapy and
supportive treatments have become more important for
increasing overall survival and disease free survival in
patients with breast cancer. To ensure long-term cen-
tral venous access, the TIVAP has been extensively used
and is now widely accepted as an effective catheter [29].
Our results show that TIVAP implantation via US-guided
IJV is safe and feasible in the long-term use by breast can-
cer patients requiring chemotherapy and parenteral nutri-
tion. Chemotherapy and/or fluid administration on the
TIVAP implantation day appear safe without an increased
risk of acute and chronic complications.
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